Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas

Modern Pathology

Volumn 24, Issue 9, 2011, Pages 1237-1247

  Hong, Seung Mo ^a   Li, Ang ^a   Olino, Kelly ^a   Wolfgang, Christopher L ^a   Herman, Joseph M ^a   Schulick, Richard D ^a   Iacobuzio Donahue, Christine ^a   Hruban, Ralph H ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Adenocarcinoma; E cadherin; epithelial mesenchymal transition; pancreas; prognosis; survival

Indexed keywords

UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; CADHERINS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80052413002     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.74     Document Type: Article

References (58)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671-1677.
3. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
4. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72;discussion 72-63.
5. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7:4115-4121. (Pubitemid 34044636)
6. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009;15:4674-4679.
7. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003; 63:4158-4166. (Pubitemid 36917941)
8. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-3742. (Pubitemid 36793060)
9. Sato N, Goggins M. Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 2006;13:280-285. (Pubitemid 44111335)
10. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 2006;13:286-295. (Pubitemid 44111336)
11. Sato N, Matsubayashi H, Abe T, et al. Epigenetic downregulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005;11:4681-4688. (Pubitemid 41557185)
12. Fukushima N, Sato N, Ueki T, et al. Preproenkephalin and p16 gene CpG island hypermethylation in pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma. Am J Pathol 2002;160: 1573-1581. (Pubitemid 34525637)
13. Sato N, Ueki T, Fukushima N, et al. Aberrant Methylation of CpG Islands in intraductal papillary mucinous neoplasms of the pancreas increases with histological grade. Gastroenterology 2002;123: 1365-1372.
14. Sato N, Fukushima N, Hruban RH, et al. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol 2008;21:238-244. (Pubitemid 351304281)
15. Li A, Omura N, Hong SM, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010;70:5226-5237.
16. Sato N, Fukushima N, Chang R, et al. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 2006;130:548-565. (Pubitemid 43202051)
17. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-325. (Pubitemid 350003021)
18. Akada M, Crnogorac-Jurcevic T, Lattimore S, et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 2005;11:3094-3101. (Pubitemid 40525216)
19. Erkan M, Kleeff J, Esposito I, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005;24:4421-4432. (Pubitemid 40961765)
20. Winter JM, Ting AH, Vilardell F, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008; 14:412-418. (Pubitemid 351226108)
21. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806-1813.
22. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Expression patterns of alpha-, beta-and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. Anticancer Res 2001;21:4127-4134. (Pubitemid 34229299)
23. Li YJ, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. World J Gastroenterol 2003;9:368-372.
24. Masugi Y, Yamazaki K, Hibi T, et al. Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer. Hum Pathol 2010;41:1061-1068.
25. Joo YE, Rew JS, Park CS, et al. Expression of E-cadherin, alpha-and beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology 2002;2: 129-137.
26. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
27. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000;60:1835-1839. (Pubitemid 30207640)
28. von Burstin J, Eser S, Paul MC, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009;137:361-371
29. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
30. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907. (Pubitemid 351482843)
31. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB and SIP. Nat Cell Biol 2008;10:593-601. (Pubitemid 351627379)
32. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-14914.
33. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-6929.
34. Halbleib JM, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 2006;20:3199-3214. (Pubitemid 44904842)
35. Cao D, Maitra A, Saavedra JA, et al. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol 2005;18: 752-761. (Pubitemid 40780508)
36. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009;119: 1420-1428.
37. Wang Z, Li Y, Kong D, et al. Acquisition of epithelialmesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009;69:2400-2407.
38. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009;69:5820-5828.
39. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher0s conceptual friend and foe. Am J Pathol 2009;174:1588-1593.
40. Kloppel G, Hruban RH, Longnecker DS, et al. Ductal adenocarcinoma of the pancreas. In: Hamilton SR, Aaltonen LA (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System Vol 2 IARCPress: Lyon, 2000;211-230.
41. McShane LM AD, Sauerbrei W, Taube SE, et al. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-9072.
42. Cao D, Zhang Q, Wu LS, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 2007;20:570-578. (Pubitemid 46631999)
43. Asiyanbola B GA, Herman JM, Choti MA, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 2009;13:752-759.
44. House MG, Guo M, Iacobuzio-Donahue C, et al. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003;24:193-198. (Pubitemid 36267086)
45. Dansranjavin T, Mobius C, Tannapfel A, et al. E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncol Rep 2006;15:1125-1131.
46. Lim SC, Lee MS. Significance of E-cadherin/betacatenin complex and cyclin D1 in breast cancer. Oncol Rep 2002;9:915-928.
47. Rakha EA, Abd El Rehim D, Pinder SE, et al. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005;46:685-693. (Pubitemid 40834828)
48. Shin SJ, Kim KO, Kim MK, et al. Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer. Jpn J Clin Oncol 2005;35:342-348. (Pubitemid 41444283)
49. Torer N, Kayaselcuk F, Nursal TZ, et al. Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J Surg Oncol 2007;96:419-423. (Pubitemid 47519448)
50. Gould Rothberg BE, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat 2006;100:139-148. (Pubitemid 44631915)
51. Graff JR, Gabrielson E, Fujii H, et al. Methylation patterns of the E-cadherin 50 CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000;275:2727-2732. (Pubitemid 30082043)
52. Fujita Y, Krause G, Scheffner M, et al. Hakai, a c-Cbllike protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002;4: 222-231. (Pubitemid 34218196)
53. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-829. (Pubitemid 351757205)
54. Marambaud P, Shioi J, Serban G, et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002;21:1948-1956. (Pubitemid 34437192)
55. Karayiannakis AJ, Syrigos KN, Chatzigianni E, et al. Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer. Anticancer Res 1998;18:4177-4180. (Pubitemid 29043631)
56. Li YJ, Meng YX, Ji XR. Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer. Hepatobiliary Pancreat Dis Int 2003;2:471-477.
57. Pignatelli M, Ansari TW, Gunter P, et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994;174:243-248.
58. Vincent A, Herman JM, Schulick R, et al. Pancreatic cancer. Lancet 2011 (in press).